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Dientamoeba fragilis belongs to the trichomonad group of protozoan parasites and it has been implicated
as a cause of gastrointestinal disease with world-wide prevalences ranging from 0.5% to 16%. The major-
ity of patients with dientamoebiasis present with gastrointestinal complaints. Chronic symptoms are
common with up to a third of patients exhibiting persistent diarrhoea. Numerous studies have success-
fully demonstrated parasite clearance, coupled with complete resolution of clinical symptoms following
treatment with various antiparasitic compounds. Treatments reported to be successful for dientamoebi-
asis include carbarsone, diphetarsone, tetracyclines, paromomycin, erythromycin, hydroxyquinolines and
the 5-nitroimidazoles, including metronidazole, secnidazole, tinidazole and ornidazole. It is of note that
most current treatment data is based only on small number of case reports. No large scale double blind
randomised placebo controlled trials testing the efﬁcacy of antimicrobial agents against D. fragilis has
been undertaken highlighting the need for further study. In addition there is very little in vitro suscepti-
bility data available for the organism making some current treatment options questionable. The aim of
this review is to critically discuss all treatment options currently available for dientamoebiasis.
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Dientamoeba fragilis is a trichomonad parasite which has been
implicated as a cause of gastrointestinal disease. Despite the fre-
quency of this organism being encountered it continues to be ne-
glected as a signiﬁcant pathogen with many laboratories not
routinely performing adequate laboratory diagnostic testing for
the parasite (Windsor and Johnson, 1999; Johnson et al., 2004;
Stark et al., 2006, 2010; Barratt et al., 2011b). The prevalence of
D. fragilis varies widely with recent studies ﬁnding D. fragilis to
be the most common pathogenic protozoan found in stool when
appropriate diagnostic methods are utilised (Crotti and D’Annibale,
2007; Rayan et al., 2007).
The clinical presentation of dientamoebiasis varies from asymp-
tomatic carriage to symptoms ranging from altered bowel motions,
abdominal discomfort, nausea and diarrhea with associated eosin-
ophilia reported in up to 50% of paediatric and 10% of adult pa-
tients (Preiss et al., 1991; Cuffari et al., 1998; Stark et al., 2010).
Studies have shown that dientamoebiasis may cause irritable bo-
wel syndrome (IBS) – like symptoms (Stark et al., 2007b), and
chronic symptoms ranging from weeks to months have been re-
ported for general populations in the scientiﬁc literature.
The life cycle and mode of transmission of D. fragilis are poorly
deﬁned. Some researchers have suggested the mode of transmis-
sion occurs via a helminth vector, while others suggest direct
transmission from infected patients the most likely route of trans-
mission (Ockert and Schmidt, 1976; Stark et al., 2005, 2006; Gir-
ginkardesler et al., 2008). Currently transmission of Dientamoeba
remains a mystery and further study is required to describe its
complete life cycle (Barratt et al., 2011a).
Despite the abundance of reports in the scientiﬁc literature
regarding infections with this parasite and the fact that it was dis-
covered nearly 100 years ago, very little research has been con-
ducted on the use of suitable antimicrobial compounds. The
balance of scientiﬁc evidence currently supports the pathogenic
potential of D. fragilis and various antimicrobial compounds have
been shown to be effective for treating dientamoebiasis with both
clearance of parasite and resolution of symptoms achievable. Com-
pounds reported to be effective in treating dientamoebiasis include
clioquinol (Bosman et al., 2004), doxycycline (Preiss et al., 1991),
iodoquinol (Spencer et al., 1979b; Preiss et al., 1991; Cuffari
et al., 1998; Stark et al., 2010), metronidazole (Preiss et al., 1991;
Cuffari et al., 1998; Vandenberg et al., 2006; Kurt et al., 2008; Stark
et al., 2010), ornidazole (Kurt et al., 2008), oxytetracycline (Preiss
et al., 1991), paromomycin (Simon et al., 1967; Vandenberg et al.,
2006, 2007; Stark et al., 2010) and secnidazole (Girginkardesler
et al., 2003). However, it must be noted that most of these reports
are based upon case studies and no large-scale randomised double
blinded control trials have been undertaken on D. fragilis treatment
regimens to date (Stark et al., 2010).
It is of note that no comprehensive review on the treatment op-
tions for D. fragilis infection has been published to date, although
progress has been made in deﬁning the clinical disease (Stark
et al., 2010; Barratt et al., 2011b). The aim of this review article
is to provide an overview of all antimicrobial compounds described
in the scientiﬁc literature for the treatment of dientamoebiasis in
order to aid healthcare professionals with the selection of current
treatment options available.2. Clinical aspect
Not long after D. fragilis was described as a non-pathogenic
amoeba in 1918, researchers began to question the assumptions
made by Jepps and Dobell regarding the pathogenic nature of the
organism. A study in the Philippines less than a year later in1919 found three cases of D. fragilis in 100 symptomatic children
(Haughwout and Horrilleno, 1920). The following year Jepps de-
scribed ten cases of D. fragilis from 971 symptomatic soldiers at a
war hospital (Dobell, 1940). These reports led to an increased
interest in the parasite and ﬁve years later D. fragilis was reported
and implicated as a potential pathogen throughout the world (Tal-
iaferro and Becker, 1924).
Wenrich et al. (1936) reported an incidence of 4.3% of D. fragilis
from 1060 university students in the USA. They found that there
was a higher rate of gastrointestinal symptoms in the students in-
fected with D. fragilis than those infected with Entamoeba histolyti-
ca, with diarrhoea and abdominal pain present in the majority of
cases. However, it was not known at this time that E. histolytica
consisted of two species, E. histolytica and Entamoeba dispar, the
latter of which is considered to be non-pathogenic and much more
common than the former.
The same year Hakansson (1936) described a case of D. fragilis
infection in a 48-year-old physician (himself) who complained of
gastrointestinal symptoms including pain in the upper abdomen,
mucoid stool, loss of appetite and irritation of the rectum. After
2 weeks of recurrent symptoms he was treated with carbarsone,
which led to complete resolution of symptoms and negative
post-therapy stool samples. A year following these ﬁndings,
Hakansson (1937) undertook a follow-up study where 12 patients
with D. fragilis infections were treated with carbarsone, which re-
sulted in complete resolution of symptoms with clearance of
parasites.
In support of early ﬁndings, numerous studies over the follow-
ing 75 years have subsequently shown the pathogenic potential of
D. fragilis and demonstrated that it is a commonly encountered
enteropathogen associated with signs of clinical disease such as
diarrhea and other gastrointestinal complaints (Windsor and Mac-
farlane, 2005; Vandenberg et al., 2006; Kurt et al., 2008; Stark et al.,
2010). Crotti and D’Annibale (2007) analysed stool specimens from
1989 subjects and while Giardia intestinalis was present in 1.8% of
subjects, D. fragilis was detected in 4.1%. It was also demonstrated
that D. fragilis was more commonly associated with clinical symp-
toms than G. intestinalis. More recently, Stark et al. (2010) exam-
ined 750 symptomatic and asymptomatic patients, detecting D.
fragilis at a prevalence of 5.2%, more common than G. intestinalis.
Similarly, most of the infected patients exhibited clinical symp-
toms largely consisting of diarrhea (30/36); loose stools (26/36);
and abdominal pain/discomfort (28/36). Shedding of the parasite
was found to be highly variable. Complete resolution of symptoms
was observed in the majority of patients following treatments
including iodoquinol, paromomycin, metronidazole or combina-
tion therapy (Stark et al., 2010). Chronic infections are reported,
with one study indicating 32% of patients infected with D. fragilis
present with symptoms greater than 2 weeks in duration (Stark
et al., 2005). A recent study has also shown high rates of D. fragilis
infection amongst close household contacts of patients with dient-
amoebiasis. A total of 30% of close human contacts tested for D. fra-
gilis harbored the parasite, and the majority of these contacts
(n = 80%) were symptomatic (Stark et al., 2012).
Unfortunately, study into the pathological manifestations of D.
fragilis infections is hampered by the lack of a suitable animal mod-
el, despite previous attempts using macaques, cats, chickens and
rats, none of which have been reproducible (Dobell, 1940; Knoll
and Howell, 1946; Barratt et al., 2011a). However no recent studies
in the last 75 years have attempted to establish animal models for
the further study of D. fragilis. In addition, while a large proportion
of infected individuals present with gastrointestinal illnesses, clin-
ical presentations of D. fragilis frequently show variability and
asymptomatic carriage can occur. Intermittent shedding of the
organism is common among patients therefore care must be taken
and correct diagnostic procedures used for deﬁnitive diagnosis.
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inate the organism lead to clinical improvement (cited by Windsor
and Johnson, 1999; cited by Johnson et al., 2004; Stark et al., 2010)
and as such, D. fragilis needs to be included as a part of routine lab-
oratory diagnostics for the differential detection of enteric
protozoa.Table 1
List of treatment options for dientamoebiasis recommended by the centre for Disease
Control as of 2012.a
Drug of choice Alternative drugs
Iodoquinol Paromomycin
Adults: 650 mg PO tid  20 days Adults: 25–35 mg/kg/day PO in 3
doses  7 days
Paediatric: 30–40 mg/kg/day (max.
2 g) PO in 3 doses  20 days
Paediatric: 25–35 mg/kg/day PO in
3 doses  7 days
Tetracycline
Adults: 500 mg PO qid  10 days
Paediatric: 40 mg/kg/day (max. 2 g)
PO in 4 doses  10 days
Metronidazole
Adults: 500–750 mg PO
tid  10 days
Paediatric: 35–50 mg/kg/day PO in 3
doses  10 days
a The information provided by CDC Health Information for International Travel
2012: The Yellow Book.3. Treatment options
3.1. Historic treatment regimes
A number of early case reports demonstrated that the anti-
amoebic compounds, including emetine-bismuth-iodide and the
arsenic compound carbarsone to be effective for the treatment D.
fragilis infections with clinical improvements in the majority of
treated cases (Gittings and Waltz, 1927; Hakansson, 1936, 1937;
Knoll and Howell, 1946). One of the earliest studies undertaken
in the late 1920s (Wenyon, 1926a,b) reported the elimination of
D. fragilis following administration of emetine, resulting in the res-
olution of clinical symptoms and this was supported by subse-
quent studies of the administration of emetine or carbarsone
(Gittings and Waltz, 1927; Hakansson, 1936, 1937; Mollari and
Anzulovic, 1938).
First isolated by Pelletier and Magendie in 1822, emetine is an
oral agent and is an alkaloid originally derived from ipecac (dried
rhizome and roots of ipecacuanha plant); it inhibits protein syn-
thesis by restricting movement of ribosomes along mRNA, how-
ever it has signiﬁcant toxicity with a number of side effects,
including cardiac arrhythmia, gastrointestinal toxicity and neutro-
muscular reactions (Khaw and Panosian, 1995).
Carbarsone oxide (p-carbamidophenyl arsenous oxide) is an ar-
senic-based antiprotozoal compound, particularly known for its
use as an anti-amoebic treatment (Epstein, 1936). As with other ar-
senic compounds however, accumulation can lead to arsenic poi-
soning which ultimately leads to a variety of adverse health
effects and in extreme circumstances, death (Rahman et al., 2009).
Keystone et al. (1983) reported on one of the earliest toxico-
logical study of the arsenical compound, diphetarsone. Diphetar-
sone (1,2,di-(4arsonophenylamino ethane decahvdrate)) is a polar
pentavalent arsenical compound. The ﬁrst report of efﬁcacy was
against cysts of E. histolytica (Schneider and Dupoux, 1953). The
exact mechanism of action for this drug is unknown; however
it is thought that it acts directly by conversion to an active arsen-
oxide, leading to inhibition of sulphydryl enzymes (Schneider,
1957). A total of nine patients with known D. fragilis infections
were treated with 500 mg of diphetarsone, thrice daily for
10 days and parasite clearance was demonstrated in all patients
(Keystone et al., 1983). It was widely used as a ﬁrst-line
treatment for intestinal amoebiasis in France for over 25 years;
however its use was reviewed due to the concerns over enceph-
alopathy, polyneuritis, visual disturbances and severe dermatitis,
all of which have been associated with the use of arsenicals (Key-
stone et al., 1983). Due to the side effects associated with these
early treatments and the discovery of newer, less toxic alternative
compounds these antimicrobials are no longer routinely used in
clinical practise.
Erythromycin is a macrolide antibiotic which prevents protein
biosynthesis by binding to the 50S ribosomal subunit and thus
interferes with the elongation process of polypeptide chains
(Weisblum, 1995). There has only been one study to date which
investigated the use of erythromycin for treatment of dient-
amoebiasis. A total of six paediatric patients were treated with
50 mg/kg/day of erythromycin for 10 days; 50% of the patients
reported resolution of clinical symptoms and parasite clearance
(Preiss et al., 1991).The use of erythromycin is associated with a number of side ef-
fects including abdominal pain, diarrhoea, nausea, vomiting, dizzi-
ness, stomach irritation and skin rash. In addition, jaundice, heart
arrhythmias, Stevens-Johnson syndrome and tinnitus have been
reported in rare cases as severe side effects. The use of erythromy-
cin is contraindicated in pregnant women.
As the report by Preiss et al. (1991) was based only on single
case report, erythromycin cannot be recommended as a ﬁrst-line
treatment. Further study is necessary to determine the efﬁcacy in
treating D. fragilis infections.4. Current treatment regimes
4.1. Tetracyclines
Tetracyclines are a group of antimicrobial compounds that are
active protein synthesis inhibitors (Agwuh and MacGowan,
2006). This is achieved by preventing the attachment of amino-
acyl-tRNA binding to the ribosomal acceptor (A) site (Chopra and
Roberts, 2001).
The ﬁrst report of tetracycline in treating D. fragilis infections
was by Spencer et al. (1979b). Despite the deleterious effects in
children, one paediatric patient with gastrointestinal complaints
was given a course of tetracycline (250 mg twice a day (bid) for
5 days); however its outcome is unclear and authors do not state
whether tetracycline was an effective treatment (Spencer et al.,
1979b).
Following these ﬁndings, Dardick (1983) treated a 35 years old
male suffering from watery stools for several months with a course
of tetracycline (500 mg PO four times a day (qid) for 10 days) after
two courses of metronidazole (no dosage given, for 10 days) had
failed to clear D. fragilis infection. Parasite clearance and clinical
improvements were observed immediately upon initiating tetracy-
cline treatment and as such it was concluded that tetracyclinewas a
safer alternative than usingmetronidazole, iodoquinol or cabarsone
with which there are a number of known associated side effects.
Additionally, a recent case study consisting of three symptom-
atic adults suffering from Dientamoeba-associated diarrhoea last-
ing between 5 days to over 1 month were treated with a course
of tetracycline (no dosage given) with complete elimination of D.
fragilis and clinical improvements observed in all patients (Stark
et al., 2007a).
Tetracycline is an agent that is currently recommended as a
treatment option by the centres for Disease Control (CDC; see
Table 1). Such recommendations however, are based only on three
case reports each comprising of small patient populations
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tic efﬁcacy of these agents.
Additionally, two compounds closely related to tetracycline,
oxytetracycline which has a better absorption proﬁle, and doxycy-
cline with a longer elimination half-life of 16 h (Agwuh andMacGo-
wan, 2006), have been reported to be effective for dientamoebiasis.
Butler, 1996 treated a single patient with 100 mg of doxycycline
twice daily for 10 days. Within 36 h nausea and diarrhoea resolved.
Notably, Preiss et al. (1990) demonstrated the use of oxytetracy-
cline (n = 8) and doxycycline (n = 4) in paediatric patients with
known D. fragilis infections. Patients were given either drug at dif-
ferent dosages for 10 days (see Table 2). The patients treated with
oxytetracycline had clinical improvement and clearance of the par-
asite in 90% (8/9) of patients while 75% (3/4) of patients treated
with doxycline reported clinical improvement and clearance of
the parasite (Preiss et al., 1990). Once again the sample size is small
and it is difﬁcult to interpret the clinical efﬁcacy.
The use of tetracyclines is however, associated with a number of
potential side effects including photosensitivity, skin reactions,
phototoxicity and gastrointestinal upsets. Deleterious effect on
dental development has also been described and use of tetracycline
is not recommended for children under the age of eight and for wo-
men during pregnancy (Dardick, 1983; Turner, 1985).Table 2
Previous studies using recommended treatments to date for D. fragilis infections, study siz
Recommended
treatment
Study size
(n)
Treatment efﬁcacy
Diphetarsone 9 100%
Clioquinol 27 81.5%
12 83%
Iodoquinol 3 100%
12 83.3%
5 80%
5 20%
12 N/A
Paromomycin 5 100%
15 80% parasite clearance/87% clinical
improvement
4 100%
21 100%
61 98%
Tetracycline 1 100%
1 N/A
Oxytetracycline 9 90%
Doxycycline 4 75%
1 100%
Erythromycin 6 50%
Metronidazole 35 80%
56 69.6% parasite eradication/76.8% clinical
improvement
6 83.3%
15 66.7%
91 70%
5 N/A
32 12.5% parasite clearance/37.5% reduced or
recurring symptoms
3 66.7%
Metronidazole/
Tinidazole
16 68.8%
Secnidazole 35 97% parasite eradication/100% clinical
improvement (27-disappeared; 8-decreased)
Ornidazole 56 92.9% parasite eradication/96.4% clinical
improvement
Bosman et al. (2004), Butler (1996), Cuffari et al. (1998), Dardick (1983), Girginkardesler e
et al. (2003), Oxner et al. (1987), Preiss et al. (1991), Simon et al. (1967), Spencer et al. (
2007).
a ‘‘tid’’ = ‘‘ter in die’’; ‘‘three times a day’’.
b PO = Perorally.
c ‘‘qid’’ = ‘‘quater in die’’; ‘‘four times a day’’.
d ‘‘bid’’ = ‘‘bis in die’’; ‘‘twice a day’’.Based on the small number of case report studies it is not pos-
sible to recommend the use of tetracyclines for the treatment of D.
fragilis. Tetracycline is still recommended by the CDC (see Table 3)
but it needs to be reconsidered as ﬁrst-line treatment option.
4.2. Iodoquinol
Introduced in the early 1960s, iodoquinol, a poorly absorbed,
halogenated hydroxyquinoline formerly known as diiodohydroxy-
quin is a chelating agent for ferrous ions that are essential for
amoebic metabolism (Knight, 1980). It acts as a luminal amoebi-
cide but the exact mechanism of action is not known.
One of the earliest studies which reported iodoquinol treatment
of dientamoebiasis was of 32 paediatric patients (Spencer et al.,
1979b), who presented with symptomatic D. fragilis infections in
the absence of other gastrointestinal pathogens. Twelve were trea-
ted with iodoquinol (30 mg/kg/day) for 21 days (see Table 2) while
the others were given metronidazole. Although it was concluded
that treatment with either metronidazole or iodoquinol led to clin-
ical improvement, respective therapeutic efﬁcacy was not con-
ﬁrmed (Spencer et al., 1979b).
Millet et al. (1983a,b) reported on twelve symptomatic patients
treated with 650 mg of iodoquinol thrice daily for 20 days; withe, reported treatment efﬁcacy and dosage used are summarised.
Dosage used References
500 mg tida  10 days (Keystone et al., 1983)
40 mg/kg/day  10–21 days (Bosman et al., 2004)
250 mg tid  7 days (van Hellemond et al.,
2012)
650 mg POb daily  7–10 days (Stark et al., 2010)
650 mg PO tid  20 days (Millet et al., 1983a,b)
40 mg/kg/day  20 days (Cuffari et al., 1998)
20 mg/kg/day  10 days (Preiss et al., 1991)
30–40 mg/kg/day  21 days (Spencer et al., 1979a,b)
8–12 mg/kg PO daily  7–10 days (Stark et al., 2010)
25–35 mg/kg daily  7 days (Vandenberg et al., 2007)
25–35 mg/kg/day PO tid  7 days (Vandenberg et al., 2006)
25–35 mg/kg, daily  4–5 days (Simon et al., 1967)
500 mg tid  7 days (van Hellemond et al.,
2012)
500 mg qidc  10 days (Dardick, 1983)
250 mg PO bidd  5 days (Spencer et al., 1979a,b)
30–40 mg/kg/day PO qid  7 to 30 days (Preiss et al., 1991)
2 mg/kg/day PO  10 days (Preiss et al., 1991)
100 mg PO bid  10 days (Butler, 1996)
50 mg/kg/day PO  10 days (Preiss et al., 1991)
400–750 mg PO every 8 h or daily  3–10 days (Stark et al., 2010)
20 mg/kg for children; 1.5 g for adults, daily (Kurt et al., 2008)
N/A (Cuffari et al., 1998)
500–750 mg PO tid  10 days (Vandenberg et al., 2006)
30 mg/kg/day PO  10 days (Preiss et al., 1991)
250 mg PO tid  7 days (Spencer et al., 1979a,b)
N/A (Norberg et al., 2003)
500–750 mg PO tid  10 days (Oxner et al., 1987)
N/A (Bosman et al., 2004)
30 mg/kg for children; 2 g for adults, single
dose (second treatment required in one case)
(Girginkardesler et al.,
2003)
30 mg/kg for children; 2 g for adults, single
dose
(Kurt et al., 2008)
t al. (2003), Keystone et al. (1983), Kurt et al. (2008), Millet et al. (1983a,b), Norberg
1979a, b), Stark et al. (2010), van Hellemond et al. (2012), Vandenberg et al. (2006,
Table 3
Chemical structures of treatment options for D. fragilis infections.
Treatment options Chemical
formula
Molecular structure Side effects/contraindications Recommended dosagea
Carbarsone C7H9AsN2O4 Long-term exposure to As has been
associated with bladder and kidney
cancer; contraindicated for patients
with severe hepatic disease
75 mg/kg  10 days
Diphetarsone C14H18As2N2O6 Transient hepatic abnormalities,
contraindicated for patients with
severe hepatic disease
500 mg POb tidc  10 days
Tetracycline C22H24N2O8 Detrimental effects on dental
development/contraindicated for
children under the age of 5 yrs old,
renal impaired patients and during
pregnancy
500 mg PO qidd  10 days
40 mg/kg/day (max. 2 g) PO
qid  10 days
Oxytetracycline C22H24N2O9 Discolouration of teeth; affects
foetal skeletal development/
contraindicated for children under
8 yrs old, renal impaired and during
pregnancy
General: 250–500 mg PO
qid  10 days
For severe infections: 250–
500 mg PO qid  7–30 days
Doxycycline C22H24N2O8 Gastrointestinal disturbances;
esophageal ulceration;
photosensitising agent/
contraindicated for children under
the age of 8 yrs old, renal impaired
patients and during pregnancy
100–200 mg PO qde  7–14 days
1–2 mg/kg/day PO tid
Iodoquinol
(hydroxyquinoline)
C5H5I2NO Nausea; vomiting; abdominal
cramps; diarrhoea; skin irritation;
fever; chills; headache; dizziness
650 mg PO tid  7–10 days
30–40 mg/kg/day PO in three
doses  7–10 days
Clioquinol C9H5CIINO Subacute Myelo-Optico-
Neuropathy (SMON)
250 mg PO tid  7 days
40 mg/kg/day PO  10 days
Erythromycin C37H67NO13 GI disturbances; arrhythmia;
neurological reactions;
contraindicated for women during
pregnancy
500 mg PO bidf  10–14 days
30–100 mg/kg/day  10–
14 days
Paromomycin C23H47N5O18S.
H2SO4
Diarrhoea; nausea; stomach
cramps/seek medical attention for
severe allergic reactions
25–35 mg/kg/day PO
tid  7 daysg
Metronidazole C6H9N3O3 Loss of appetite; metallic taste;
headache; insomnia; vertigo;
anorexia; vomiting/seek medical
attention if experiencing severe
adverse effects
500–750 mg PO tid  10 days
35–50 mg/kg/day PO
tid  10 days
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Table 3 (continued)
Treatment options Chemical
formula
Molecular structure Side effects/contraindications Recommended dosagea
Secnidazole C7H11N3O3 GI disturbances; nausea 2 g qd PO
30 mg/kg qd PO
Ornidazole C7H10CIN33 GI disturbances; nausea; headache;
dizziness
2 g qd PO
30 mg/kg qd PO
Tinidazole C8H13N3O4S GI disturbances; bitter taste;
diarrhea; itchiness
2 g qd PO  3 days
50 mg/kg qd  3 days
a Adult and paediatric dosages shown where applicable, paediatric dosage is shown below adult dosage.
b PO = Perorally.
c ‘‘tid’’ = ‘‘ter in die’’; ‘‘three times a day’’.
d ‘‘qid’’ = ‘‘quater in die’’; ‘‘four times a day’’.
e ‘‘qd’’ = ‘‘quaque die’’; ‘‘once a day’’.
f ‘‘bid’’ = ‘‘bis in die’’; ‘‘twice a day’’.
g Universal dosage for adults and children.
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Preiss et al. (1991) used iodoquinol for ﬁve children with D. fragilis
infection, but found it to be effective in only one patient. Such ﬁnd-
ings however, may be attributed to the lower dosage of 20 mg/kg/
day of iodoquinol for 10 days, as compared with the dosage of
40 mg/kg/day for 20–21 days previously described by Spencer
et al. (1979b).
Five patients were treated with 40 mg/kg/day for 20 days in an-
other study by Cuffari and colleagues, with 4/5 patients (80%)
exhibiting clinical improvement (Cuffari et al., 1998).
In another small case series, three symptomatic patients were
treated with iodoquinol (650 mg perorally (PO), daily for 10–
12 days) with clinical and parasitological cure in all patients (Stark
et al., 2010). A recent case study reported clinical and parasitolog-
ical cure in two paediatric patients treated with iodoquinol (no
dosage given), after the initial treatment with metronidazole had
failed (Banik et al., 2011).
For treating dientamoebiasis, iodoquinol is usually given orally
at a dosage of 650 mg PO thrice daily for 20 days in adults and
40 mg/kg/day PO in three doses (max. 2 g) for 20 days in children.
There have been a number of studies reporting the side effects
associated with the use of hydroxyquinolines. The iodine compo-
nent of iodoquinol in particular, is associated with toxicity and
there have been cases of neuropathy and blindness following pro-
longed administration (Khaw and Panosian, 1995). Ingestion of a
large amount of the drug over a short period of time or a long-term
treatment can lead to toxic encephalopathy in the form of
drowsiness, mental confusion, disorientation, hallucinations and
headache with subsequent amnesia (Baumgartner et al., 1979).Given the conﬂicting results described in the literature following
iodoquinol treatment and the fact that once again the studies have
been small case series with no control groups, cautionmust be used
when using this agent for the treatment of Dientamoeba, despite it
being a CDC recommended drug for treatment (see Table 1).
4.3. Clioquinol
Clioquinol (Iodochlorhydroxyquin), a structurally related com-
pound of iodoquinol is a member of halogenated 8-hydroxyquino-
lines which has been shown to possess antiprotozoal activity (Mao
and Schimmer, 2008). It was used in the 1950s to 1970s as an oral
anti-parasitic treatment for intestinal amoebiasis; however it was
withdrawn from the market due to the 10,000 estimated cases of
neurotoxicity in Japan, a condition known as subacute myelo-opti-
co neuropathy or SMON (Tsubaki et al., 1971). It has been indicated
though, that the post-war diet in Japan may have lacked in vitamin
B12 intake and may have been a signiﬁcant contributing factor in
the SMON incidence (Tabira, 2001).
It acts as a luminal amoebicide and is bacteriostatic however
the exact mechanism of action is unknown. It has been demon-
strated though, that clioquinol is a potent inhibitor of the protea-
some (Daniel et al., 2005; Ding et al., 2005; Chen et al., 2007;
Mao et al., 2009) and has the ability to act as a zinc and copper che-
lator (Cuajungco et al., 2000).
In addition to iodoquinol, clioquinol was reported to be parasi-
tologically and clinically effective for D. fragilis infections in 27 out
of 33 (n = 82%) paediatric patients, when used at a dosage of
40 mg/kg/day for 10–21 days (Bosman et al., 2004).
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Paromomycin is an aminoglycoside antibiotic with a broad-
spectrum activity, ﬁrst isolated from Streptomyces krestomuceticus
in the 1950s. Currently it is recommended for use in amoebiasis
as a luminal agent, giardiasis and for treating Cyrptosporidium
and microsporidia (Gupta et al., 2004; Davidson et al., 2009).
The earliest study of paromomycin for dientamoebiasis was re-
ported by Simon et al. (1967). All 21 cases of D. fragilis infection
were cured by administering paromomycin at 25–35 mg/day for
4–5 days.
A recent study by Vandenberg et al. (2006) reported the treat-
ment of four symptomatic paediatric patients with paromomycin
(no dosage given) and it was shown to be parasitologically and
clinically effective in all cases after a follow-up triple faeces test
1 month later. A year later, Vandenberg et al. (2007) evaluated
the use of paromomycin in 15 paediatric patients (25–35 mg/kg/
day for 7 days) with known D. fragilis infections. Parasitic elimina-
tion and clinical improvements were observed in all patients after
1 month follow-up and in addition, no major side-effects were re-
ported. Such ﬁndings led authors to recommend paromomycin as a
ﬁrst-line treatment option for D. fragilis infections.
Another study by Stark et al. (2010) reported on treatment of
ﬁve symptomatic patients with paromomycin (8–12 mg/kg PO,
daily for 7–10 days). All patients cleared the infection, and re-
ported clinical improvement with resolution of symptoms.
A larger cohort of 93 symptomatic adult patients were included
in the retrospective study from the Netherlands (van Hellemond
et al., 2012) where these patients were treated with paromomycin
(n = 61; three daily doses of 500 mg for 7 days), along with other
drugs including clioquinol (n = 12; three daily doses of 250 mg
for 7 days), metronidazole (n = 7; three daily doses of 500 mg for
7–10 days) and doxycycline in combination with drugs mentioned
(no dosage given; with paromomycin n = 27; clioquinol n = 2; met-
ronidazole n = 1). Paromomycin was found to be the most effective
treatment and higher eradication rates of 98% was reported, in
comparison to 83% and 57% for clioquinol and metronidazole,
respectively.
Paromomycin is administered orally at a dosage of 25–35 mg/
kg/day, usually in three divided doses for a total of 5–10 days. Par-
omomycin is poorly absorbed so is unsuitable for use in systemic
infections. Similar to other aminoglycosides, side effects associated
with the use of paromomycin include vestibular, cochlear and re-
nal toxicity. All of these are considered very rare due to the poor
absorption of the drug (Davidson et al., 2009).
While the in vitro susceptibility testing for paromomycin has
previously found it to be ineffective for D. fragilis with Minimal
Lethal Concentration (MLC) of 500 lg/mL (Nagata et al., 2012),
the majority of clinical data currently supports the fact that paro-
momycin may be an effective treatment option (Simon et al., 1967;
Vandenberg et al., 2006, 2007; Stark et al., 2010; van Hellemond
et al., 2012). Most case reports have demonstrated successful treat-
ment of dientamoebiasis with paromomycin, coupled with low
incidences of adverse events. Despite this, the number of studies
using paromomycin for treatment of dientamoebiasis is surpris-
ingly small and further studies are required. However it is still rec-
ommended as a treatment option by the CDC (see Table 1).5. 5-Nitroimidazoles
5.1. Metronidazole
Developed in 1962, metronidazole is an oral synthetic antipro-
tozoal and antibacterial compound, originally indicated for man-
agement of trichomoniasis (Löfmark et al., 2010; Chaudhari andSingh, 2011). It is a prodrug, which forms active metabolites upon
reduction by ﬂavin enzymes within the cytoplasm of trophozoites.
Reduction of the parent compound leads to either a single elec-
tron transfer reduction product, a nitroimidazole nitroradical anion
or further reduced reactive intermediates, i.e. nitrosoimidazole or
hydroxyamineimidazole (Moreno and Docampo, 1985). Such
reduction takes place in microaerophilic, anaerobic and even in
aerobic conditions (Perez-Reyes et al., 1980; Viode et al., 1999).
However the presence of oxygen in aerobic condition leads to reox-
idation of reactive intermediates back into the parent compound, a
redox cycling effect termed ‘‘futile cycle’’ (Lloyd and Pedersen,
1985). It is both a luminal and tissue amoebicide as it is active in
both the intestinal lumen/wall, and at extra-intestinal sites follow-
ing oral administration.
There have been mixed reports in the literature regarding the
efﬁcacy of metronidazole for the treatment of D. fragilis infection.
While it has been shown to be effective in some studies, others re-
port treatment failures and relapses.
In a retrospective study of 35 paediatric patients, D. fragilis was
found to be the only parasite in the gastrointestinal tract in 32 indi-
viduals with clinical symptoms. Peripheral blood eosinophilia was
present in half of children examined (Spencer et al., 1979b). Eigh-
teen patients were treated with either iodoquinol (n = 12), tetracy-
cline (n = 1) or metronidazole (n = 5). Twelve patients completed
the course of therapy and returned for follow-up evaluation. Re-
infection was reported in two cases (Spencer et al., 1979b). The
authors conclude that all treatments led to symptomatic relief
and parasitic clearance, however therapeutic efﬁcacy for each drug
was not provided and it is not known which drug was associated
with failure to complete the treatment course.
Another study described treatment of three symptomatic pa-
tients with a course of metronidazole (dosage not given). One pa-
tient subsequently required a further course of combination
treatment consisting of metronidazole and oxytetracycline for suc-
cessful elimination of the organism (Oxner et al., 1987).
Preiss et al. (1991) was the ﬁrst to examine metronidazole in a
larger sample size. The authors used metronidazole, 30 mg/kg/day
for 10 days in children and found it to be effective in 70% out of the
91 cases treated. As 30% of the cases required up to three follow-up
treatments for complete resolution of parasites and symptoms, it
was suggested by the authors that metronidazole should be given
10 days at the recommended dosage, followed by oxytetracycline,
doxycycline or erythromycin.
Another study described the treatment of 32 D. fragilis infec-
tions with different doses and duration of therapy with metronida-
zole (Norberg et al., 2003). Clinical improvements were observed in
16 cases. However no speciﬁc data was given in regards to the dos-
ages used and the duration of therapy.
Vandenberg et al. (2006) treated 15 patients with a ten day
course of metronidazole. Of these, 12 patients returned for a fol-
low-up triple faeces test a month after treatment and eight pa-
tients had parasitological and clinical cure. Once again no dosage
information was given.
Successful treatment of four symptomatic adults with a course
of metronidazole (no dosage given), combined with tetracycline in
three patients was reported, with follow up stool samples negative
in all cases (Stark et al., 2007a). Following this preliminary study
35 patients were treated with metronidazole treatment at different
dosages and duration (Stark et al., 2010). While the treatment was
found to be effective in 80% (n = 28) of cases, a high rate of treat-
ment failures/relapses (6/28; 21.4%) were associated with the use
of metronidazole. The majority of treatment failures were associ-
ated with a three day course of metronidazole and were less likely
with a longer duration of therapy.
Recently 41 paediatric patients diagnosed with D. fragilis infec-
tion were treated with metronidazole (no dosage given). Complete
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85% (Banik et al., 2011). Treatment failures occurred in 15%
(n = 6) who required an additional course of metronidazole (4/6)
or iodoquinol (2/6). All became negative on follow-up stool sam-
ples (Banik et al., 2011).
Metronidazole is typically administered at 500–750 mg three
times daily for 10 days for adults and 35–50 mg/kg/day three times
a day for 10 days in paediatric patients. The safety proﬁle of met-
ronidazole is well known and the majority of side effects are con-
sidered to be mild to moderate in severity. A variety of adverse
events however, have been described including loss of appetite,
metallic taste, headache, insomnia, vertigo, anorexia and vomiting.
Rarely convulsive seizures and peripheral neuropathy have been
reported following prolonged treatments (Gupta et al., 2004; Löf-
mark et al., 2010). Notably, metronidazole inhibits the metabolism
of alcohol in some patients, often leading to intolerance (Löfmark
et al., 2010).
Despite the inconsistency in clinical efﬁcacy of metronidazole
with clearance of D. fragilis ranging from 66.75% to 100%, overall
metronidazole has been shown to be reasonably effective in treat-
ing dientamoebiasis (Preiss et al., 1991; Kurt et al., 2008; Stark
et al., 2010; Banik et al., 2011). However treatment failures or re-
lapses may require prolonged therapy with the potential for signif-
icant side effects.6. Possible novel treatment regimes
6.1. Secnidazole
Recently newer 5-nitroimidazole derivatives with a single oral
dose schedule such as secnidazole have been used for the treat-
ment of D. fragilis. It has a longer elimination half-life of approxi-
mately 17–29 h (compared with six to seven hours for
metronidazole (Gupta et al., 2004)). Secnidazole has been used
for the treatment of giardiasis, trichomoniasis and all symptomatic
forms of amoebiasis with recorded parasitological cure rates of 80–
100%, similar to the response rates achieved through multiple
doses of metronidazole or tinidazole (Gillis and Wiseman, 1996).
Girginkardesler et al. (2003) screened 400 stool samples for the
presence of pathogenic protozoans, with D. fragilis detected in 35.
All patients were treated with a single oral dose of secnidazole
and D. fragilis was eradicated in 34 patients. A second dose was re-
quired in one patient, who was given an identical dose and a fol-
low-up evaluation showed parasitic clearance seven days after
the second treatment. These ﬁndings, coupled with the mild nau-
sea reported in two patients the only side effect led the authors
to recommend secnidazole as an effective therapeutic option.6.2. Ornidazole
Ornidazole is similar in efﬁcacy to metronidazole; however it
possesses a longer half-life and is given as a single oral dose. The
side effect proﬁle of the drug is more favourable than metronida-
zole, with lesser side effects including nausea and bitter taste in
mouth (Gupta et al., 2004).
Kurt et al. (2008) undertook one of the few randomised and
double-blinded studies, comparing the efﬁcacy of metronidazole
and ornidazole in 112 patients with D. fragilis infection, who were
randomised into two treatment groups: group 1 (n = 56), who re-
ceived metronidazole, 20 mg/kg/day for children; 1.5 g/day for
adults for 5 days; and group 2 (n = 56), who received a single oral
dose of ornidazole (30 mg/kg for children; 2 g for adults). Stool
examinations were undertaken 7 and 14 days following treatment.
Ornidazole resulted in clinical cure in 54 patients (96.4%) with par-
asite eradication in 52/56 (92.9%). In comparison the clinical curerate for metronidazole was only 76.8% with parasite eradication
in 69.6% (Kurt et al., 2008). Only minor side-effects were recorded
for six patients in the ornidazole group. These consisted of nausea,
headache and dizziness. In contrast 18 patients complained of
numerous side-effects when treated with metronidazole, including
nausea, metallic taste, vomiting, anorexia, dizziness, insomnia, ver-
tigo and dry mouth (Kurt et al., 2008). These results led the authors
to recommend ornidazole as a novel agent for the treatment of
dientamoebiasis.
6.3. Tinidazole
A structural analogue of metronidazole, tinidazole has been
used in Europe, Australia and in a number of developing countries
for decades, and it was recently approved by the Food and Drug
Administration for the treatment of trichomoniasis, giardiasis,
amoebiasis and amoebic liver abscess (Fung and Doan, 2005). In
addition to a longer half-life (12 h) it is reported to be better toler-
ated than metronidazole and the cure rates for protozoan infec-
tions are higher (Gupta et al., 2004).
A retrospective study of 23 paediatric patients with symptom-
atic D. fragilis infections, who were treated with metronidazole
(50 mg/kg/day bid for 7 days) or tinidazole (single dose of 50 mg/
kg, maximum of 2 g) was undertaken. Therapeutic efﬁcacy were
compared with those of a control group (n = 41), consisting of un-
treated patients (cited in Bosman et al., 2004). While clinical reso-
lution or improvements were observed in 60.9% of treated group,
individual treatment efﬁcacy was not described. Therefore it is dif-
ﬁcult to determine the impact of tinidazole in this study.
Recommended dosages of secnidazole and ornidazole are 2 g as
a single dose for adults and 30 mg/kg a day for children, while
tinidazole is given in dosages of 2 g a day for adults and 50 mg/
kg/day (maximum of 2 g) for children, for a total of 3 days (Gupta
et al., 2004). The pharmacokinetic proﬁles of these nitroimidazole
derivatives are similar to those of metronidazole, but they have
longer elimination half-lives and in most cases demonstrate clini-
cal improvements with only one to three doses of the drug (Lau
et al., 1992).
The newer 5-nitroimidazole derivatives have been shown to be
more effective treatment options available for D. fragilis. Addition-
ally, uses of such treatments are associated with far fewer side ef-
fects when compared with metronidazole and may be considered
as drugs of choice for the treatment of D. fragilis. As such, they
should be considered the ﬁrst-line treatment option for cases of
symptomatic infections if no other possible pathogens are present.
6.4. Nitazoxanide
Nitazoxanide (2-acetolyloxy-N-(5-nitro-2-thiazolyl benzamide)
was ﬁrst introduced in 1984 as a human cestocidal drug (Rossignol
and Maisonneuve, 1984). It is the parent compound of a class of
drugs collectively named thiazolides (Gilles and Hoffman, 2002;
White, 2004; Fox and Saravolatz, 2005). In contrast to the nitroim-
idazoles, recent studies have indicated that nitazoxanide inhibits
pyruvate:ferredoxin oxidoreductase (PFOR) directly and is not
dependent on ﬂavin metabolism (Gilles and Hoffman, 2002;
Hemphill et al., 2006; Leitsch et al., 2010). In vitro studies have
demonstrated nitazoxanide inhibits Trichomonas vaginalis (Adagu
et al., 2002; Cedillo-Rivera et al., 2002) and it has been shown to
be a noncompetitive inhibitor of the PFOR of T. vaginalis, E. histoly-
tica and G. intestinalis (Hoffman et al., 2007).
Clinical trials have shown nitazoxanide to be effective in the
treatment of diarrhoea caused by E. histolytica, G. intestinalis and
Cryptosporidium parvum, in particular organisms displaying high
levels of resistance to metronidazole (Abboud et al., 2001; Hemp-
hill et al., 2006). Adverse effects associated with nitazoxanide have
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to be lower than metronidazole, albendazole or praziquantel (Gil-
les and Hoffman, 2002).
The number of reports of nitazoxanide as treatment for dient-
amoebiasis is limited. A single case report has shown nitazoxanide
in combination with secnidazole and doxycycline to be effective
for treatment (n = 2), with total parasitological clearance and com-
plete resolution of symptoms (Stark et al., 2009). However both pa-
tients complained of side effects and no dosage data is available,
thus it is difﬁcult to determine whether side effects were due to
nitazoxanide alone or other components of the combination ther-
apy. It is surprising that no larger studies have been undertaken
to determine the therapeutic potential of this compound given
the low toxicity and potential clinical efﬁcacy.
Nitazoxanide is administered as an oral suspension of 20 mg/
mL or in tablet formulation at a dosage of 500 mg. The recom-
mended dosage for adults this is 500 mg/day (Hemphill et al.,
2006). Following oral administration, the drug is absorbed from
the gastrointestinal tract and absorption is doubled when taken
with food (Stockis et al., 2002). Side effects are generally mild
and transient and may include abdominal pain, diarrhoea and nau-
sea. More than 2000 patients have participated in a variety of clin-
ical trials with less than 1% experiencing more severe symptoms,
including anorexia, ﬂatulence, increased appetite, enlarged salivary
glands and dizziness (Hemphill et al., 2006).
Although nitazoxanide appears to be a viable candidate for fu-
ture treatment options of D. fragilis infections there has only been
one case study to date, thus it is impossible to determine the effec-
tiveness of this agent. Further studies are required.6.5. Furazolidone
Furazolidone (N-5-nitro-2-furfurylidene amino-2-oxazolidine)
is a synthetic nitrofuran derivative used for the treatment of a
broad range of bacterial and protozoal infections. In particular,
furazolidone has activity against E. histolytica and Giardia and it
is considered to be an alternative compound in the case of treat-
ment failure of ﬁrst line agents such as the 5-nitroimidazole com-
pounds (Escobedo et al., 2009; Lalle, 2010). Like metronidazole,
furazolidone is activated by the reduction in trophozoites; how-
ever it is likely to be mediated by NADH oxidase (Brown et al.,
1996; Upcroft and Upcroft, 1998). It is also more efﬁcient than
nitazoxanide in the in vitro reduction of cyst production and possi-
bly affects the mechanism of endocytosis of the Giardia cells (Hau-
sen et al., 2006).
For treatment of giardiasis, furazolidone is administered at
100 mg for adults and 1.25–2 mg/kg for children, four times a
day for 7–10 days. Although it is generally well-tolerated, a minor-
ity of patients have reported gastrointestinal symptoms including
nausea, vomiting and abdominal pain. Brown discolouration of
the urine and hemolysis can occur in G6PDH-deﬁcient patients
(Gardner and Hill, 2001).
As there have been no studies to date which tested on the efﬁ-
cacy of furazolidone for treatment of dientamoebiasis, further
studies are required before its use in a clinical setting. However
this agent may have a role in treating D. fragilis infection.7. Antibiotic susceptibility testing
The ﬁrst antimicrobial studies on D. fragilis were performed in
the 1950s by Balamuth (1953). A mono-phasic medium containing
egg yolk/liver infusion capable of supporting the growth of D. fra-
gilis was developed and used to study the effects of six antimicro-
bial compounds: emetine-bismuth-iodide; vioform; carbarsone
oxide; prodigiosin; aureomycin; and a dithio-derivative of carbar-sone oxide, known as C.C. no. 914 (Balamuth, 1953). It was sug-
gested by the author that the use of arsenical compounds or
prodigiosin were the best options for treatment of D. fragilis infec-
tion. However none of these compounds are in use today.
In vitro antimicrobial susceptibility testing for current treat-
ment options using the ATCC strain of D. fragilis (ATCC 30948),
grown in a dixenic culture was undertaken by Chan et al. (1994).
The minimal amoebicidal concentrations for iodoquinol, paromo-
mycin, tetracycline and metronidazole were determined as 128,
16, 32 and 32 lg/mL, respectively. It may be difﬁcult to relate these
results to situations in vivo, as there have been no reports of clinical
infections caused by ATCC strain of D. fragilis, known to be
genotype 2, while nearly all clinical isolates of D. fragilis that
have undergone genotyping are genotype 1, the predominant
strain worldwide (Peek et al., 2004; Stark et al., 2005; Bart et al.,
2008).
More recently, susceptibility testing of a number of potential
therapeutic agents has been undertaken. Compounds tested in-
clude the newer 5-nitroimidazole derivatives and a number of pre-
viously untested compounds: diloxanide furoate; furazolidone;
nitazoxanide and ronidazole using four clinical isolates of D. fragi-
lis. The long acting 5-nitroimidazoles were found to be the most
effective, with MLCs for ornidazole, tinidazole, ronidazole, metro-
nidazole and secnidazole of 16, 16, 31, 31 and 63 lg/mL, respec-
tively (Nagata et al., 2012). While these ﬁndings, particularly
MLCs obtained for metronidazole were in agreement with the
study by Chan et al. (1994), conﬂicting results were obtained for
a number of agents tested. For example, Chan and colleagues re-
ported that the minimal amoebicidal concentrations for iodoqui-
nol, paromomycin and tetracycline were 128, 16 and 32 lg/mL,
in comparison to the recent study with 500, 500 and 250 lg/mL,
respectively which can be explained in part by methodology differ-
ences (Nagata et al., 2012). Additionally, previously untested com-
pounds demonstrated minimal inhibition of D. fragilis with MLCs
obtained for diloxanide furoate, furazolidone and nitazoxanide of
>500, 250–500 and 63 lg/mL, respectively.
As such studies are undertaken in the presence of bacterial ﬂora,
the absence of axenic culture for D. fragilis makes interpretation of
in vitro susceptibility testing difﬁcult, especially for clinical iso-
lates. Elimination of certain and/or the majority of the bacterial
ﬂora may indirectly result in detrimental effects to D. fragilis tro-
phozoites, as they have been long known to utilise them as a food
source (Nagata et al., 2012).8. Conclusion
Given the number of reports linking gastrointestinal illnesses
with D. fragilis, there is little doubt concerning the pathogenic po-
tential of this parasite. Indeed, a number of studies have shown
that D. fragilis is often more prevalent than G. intestinalis in cases
of diarrhoeal disease (Crotti et al., 2005; Vandenberg et al., 2006;
Crotti and D’Annibale, 2007; Stark et al., 2010). Moreover, treat-
ment of patients harboring D. fragilis can eradicate the organisms
and results in complete resolution of clinical symptoms. As such,
D. fragilis should be included as part of a routine laboratory diag-
nostic investigation and symptomatic patients should be treated
in the absence of other possible etiological agents.
Currently the use of iodoquinol, paromomycin, metronidazole,
tetracycline or a combination therapy is given as recommended
treatments (Stark et al., 2010). Recent case reports and non-ran-
domised studies have indicated the newer 5-nitroimidazole deriv-
atives, namely ornidazole and secnidazole to be effective options
for treatment (Girginkardesler et al., 2003; Kurt et al., 2008). In
addition in vitro susceptibility testing of clinical isolates has
indicated a number of 5-nitroimidazole derivatives, including
N. Nagata et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 204–215 213ornidazole, ronidazole and tinidazole, to be potentially effective
therapy treatment, with the MLC for some isolates as low as
8 lg/mL (Nagata et al., 2012).
Despite the number of small studies and case series showing
clinical improvement with treatment, there is little information
available concerning the optimal therapeutic options for D. fragilis
infections. Although some of these agents are now unavailable due
to their toxicity and adverse effects, the treatments reported to be
successful for dientamoebiasis to date include: carbarsone (Knoll
and Howell, 1946; Kean and Malloch, 1966); diphetarsone (Desser
and Yang, 1976; Keystone et al., 1983); tetracyclines (Kean and
Malloch, 1966; Dardick, 1983; Preiss et al., 1990; Butler, 1996;
Stark et al., 2007a); iodoquinol (Spencer et al., 1979a, 1982; Millet
et al., 1983a,b; Shein and Gelb, 1983; Cuffari et al., 1998); paromo-
mycin (Cuffari et al., 1998); erythromycin (Preiss et al., 1991); and
metronidazole (Spencer et al., 1979a; Cuffari et al., 1998). All treat-
ment options that have previously been administered are summa-
rized (see Table 3).
It is notable that no randomised double-blind, placebo con-
trolled trials have been undertaken for the evaluation of treatment
of dientamoebiasis. Additionally, a number of studies have used
relatively small sample sizes ranging from one or two patients to
over 50 (median = 17), with no control groups. Given that the rate
of spontaneous eradication of the parasite and the ‘self-limiting’
characteristics of D. fragilis infections is unknown further adds to
the confusion when evaluating potential drugs for therapy of
dientamoebiasis if an appropriate control group is not utilised.
Notably, one study has reported spontaneous eradication in 41%
of untreated cases of D. fragilis infections (van Hellemond et al.,
2012). Many if not all studies on the efﬁcacy of antimicrobial com-
pounds against D. fragilis infections utilised microscopy for the
screening of Dientamoeba which given the intermittent shedding
of the parasite may lack sensitivity. The use of molecular tech-
niques with higher speciﬁcity and sensitivity such as PCR could
clarify therapeutic success (or failure) by demonstrating the pres-
ence or absence of the parasite.
There have been reported cases of treatment failure and relapse
in the treatment of D. fragilis infection and the emergence of drug
resistance may be a concern, especially for the compounds such as
metronidazole or furazolidone. Such ﬁndings have been reported
and resistance has been induced successfully for G. intestinalis
and T. vaginalis in vitro (Cerkasovova et al., 1988; Townson et al.,
1992, 1994; Kulda et al., 1993; Upcroft and Upcroft, 1993; Brown
et al., 1999; Rasoloson et al., 2002). It should be noted that treat-
ment failure may also be attributed to poor compliance due to side
effects or inadequate drug dosage. Clinicians also need to exclude
re-infection.
In summary while a number of drugs have been shown to be
effective for treating D. fragilis infection and antimicrobial agents
such as metronidazole, paromomycin, iodoquinol and tetracycline
and are among those recommended by the CDC (see Table 1) such
recommendations, are based only on small numbers of non-ran-
domised studies. Until large scale treatment trials incorporating
properly randomised control groups are conducted, physicians
should carefully monitor the efﬁcacy and toxicity of current thera-
peutic regimes.References
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